期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 208, 期 8, 页码 1585-1593出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20101785
关键词
-
资金
- EU [European Union/BMBF-0315207A]
- Deutsche Forschungsgemeinschaft [TRR54]
- Berliner Krebsgesellschaft
- Max Planck Innovation Fonds
The transcription factor E2A is essential for lymphocyte development. In this study, we describe a recurrent E2A gene deletion in at least 70% of patients with Sezary syndrome (SS), a subtype of T cell lymphoma. Loss of E2A results in enhanced proliferation and cell cycle progression via derepression of the protooncogene MYC and the cell cycle regulator CDK6. Furthermore, by examining the gene expression profile of SS cells after restoration of E2A expression, we identify several E2A-regulated genes that interfere with oncogenic signaling pathways, including the Ras pathway. Several of these genes are down-regulated or lost in primary SS tumor cells. These data demonstrate a tumor suppressor function of E2A in human lymphoid cells and could help to develop new treatment strategies for human lymphomas with altered E2A activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据